Buy & Sell Avalanche Treasury Corporation Class A Common Stock (AVAT) – Avalanche Treasury Corporation Class A Common Stock Price Today
Aura AI Summary
Key Stats
- $50.74MMarket Cap
- FinancialsSector
- -72%3M Drawdown
- $50.74MEnterprise Value
- -Dividend Yield
- 45% Buy | 55% SellTrading Activity
- 2 daysTypical Hold Time
Avalanche Treasury Corporation Class A Common Stock (AVAT) is currently valued at a market capitalization of $50.74M, with an enterprise value of $50.74M. Over the past 52 weeks, Avalanche Treasury Corporation Class A Common Stock has traded between a low of $0.95 and a high of $10.75, highlighting its annual price range. Over the past three months, Avalanche Treasury Corporation Class A Common Stock has recorded a drawdown of -72%, reflecting recent price volatility. On average, investors hold Avalanche Treasury Corporation Class A Common Stock for approximately 2 days, indicating typical investor behavior on the platform.
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Most Recent News
Capital Link Shipping launches new CEO insights on tanker markets, maritime resilience, and capital markets.
Capital Link Shipping has expanded its Maritime Intelligence Hub with new executive insights from leaders at Scorpio Tankers, DHT Holdings, d’Amico International Shipping, and others. These discussions cover market trends in crude oil and product tan...

Centene offers voluntary staff buyouts amid major ACA membership drop
Centene, a major U.S. health insurer, has launched a voluntary separation program allowing eligible employees to apply for buyouts as it faces a significant decline in membership, especially in its Affordable Care Act (ACA) marketplace plans. Members...

US agency proposes broader Medicare coverage for heart valve device, boosting Edwards Lifesciences.
The US Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients with symptomatic severe aortic stenosis. CMS also suggested...
